Group items tagged

The Royal Pharmaceutical Society has appointed communications agency to lead a review into how it can develop and strengthen member participation. "We've appointed communications consultancy Luther Pendragon to carry out an independent review of the participation of members and of our communications concerning decisions we take on behalf of the profession through our Governance boards," the Society said in a statement on Tuesday (May 10). It added that review would examine how RPS members, elected members and stakeholders can feel engaged, informed and empowered to influence decisions about RPS policy and understand why decisions around organisational policy have been taken on their behalf by elected representatives. It will also ensure RPS decision-making processes are open and transparent with an emphasis on evidence-based decision making, and recommend ways elected members are enabled to be publicly accountable for decisions taken by the organisation at Board and Assembly level.

End of life decisions can be hard for us to make. There is so much happening quickly and all at once. One of the biggest decisions you will make will be whether you want to opt for the traditional burial process or be cremated. It can be a tough decision to make, and you may want to get your loved ones involved. This way you can understand what they want, and you can let them know what you want. It will come down to numerous deciding factors in your decision, such as religious beliefs, financial capacity and the beliefs and feeling of you and your family, so it is best that everyone is on the same page prior to your passing. Here is a look at some of the biggest advantages and disadvantages of both processes that will hopefully make your decision a tad bit easier.

The General Pharmaceutical Council's Fitness-to-Practise (FtP) committee has reversed its earlier decision ruling that a London pharmacist's statement, attributing the Grenfell tragedy to "Zionist supporters of the Tory party," amounted to the propagation of anti-Semitic tropes. In an initial 2020 hearing, the FtP committee found that a set of remarks delivered by Nazim Hussain Ali, Managing Partner of Chelsea Pharmacy Medical Clinic, through a megaphone to a crowd assembled at a Palestinian rights rally in central London in 2017 were deemed "grossly offensive," but not classified as anti-Semitic. Ali admitted his comments were offensive, but he was cleared of accusations of antisemitism and received a first warning on November 5, 2020. However, the High Court overturned this decision in June 2021 following an appeal by the Professional Standards Authority as the Judge found evidence of a "serious procedural or other irregularity" in the FtP committee's decision and instructed the GPhC to reopen the case.

The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI). Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS). "We are deeply concerned by this decision. It has left us no choice but to take legal action." "While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028." "The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS. The association had raised its full participation in the negotiations with the Government last November.

The Scottish Medicines Consortium (SMC) has accepted AbbVie's RINVOQ (upadacitinib) for use within NHS Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors. "Daily life with ulcerative colitis is difficult due to the debilitating and unpredictable nature of its symptoms", said Dr Jonathan Macdonald, Consultant Gastroenterologist at NHS Greater Glasgow and Clyde. "Clinical trials have shown that upadacitinib as a once daily pill controls symptoms in eight weeks for many patients and provided sustained responses at one year. The SMC's decision is good news for people with ulcerative colitis in Scotland as it provides an additional treatment option to help them gain control of their condition." The SMC decision is based on data from the induction studies U-ACHIEVE and U-ACCOMPLISH, as well as the Phase 3 U-ACHIEVE maintenance study, which demonstrated the efficacy of upadacitinib versus placebo in its ability to achieve clinical remission. The SMC's decision follows the granting of Marketing Authorisation for upadacitinib in UC in July 2022.

The General Pharmaceutical Council (GPhC) Fitness to Practise Committee decided to remove a pharmacist from the GPhC Register at a 'remote videolink' hearing held on 13 - 14 April. "The decision will not take effect until 12 May 2023 or, if an appeal is lodged, once that appeal has been concluded," the committee said. Kapil Ramesh Rabadia, a pharmacist first registered on 25 July 2011 with GPhC under registration number 2075823 was convicted of 'fraud by abuse of position' and 'being concerned in supplying controlled drugs' following a guilty plea on 13 September 2021. He was sentenced to 12 months imprisonment for the fraud by abuse of position and six months in respect of supplying a 3 Class B drug. However, the interim suspension set out in the decision takes effect immediately and will lapse when the removal decision takes effect or once any appeal is concluded. Between May 2018 and June 2019, Kapil ordered codeine linctus and Phenergan in excess of 100 bottles of each for four men who threatened him with knives and guns. The men told the pharmacist that he needed to continue to make the supplies or "there would be consequences" for him and his family.

The Pharmacists' Defence Association has called on the Scottish government to end unnecessary pharmacy closures and introduce emergency regulations to force companies that operate Scotland's pharmacies to open on the days and hours they have agreed. It is concerned that decisions made by some health boards in Scotland have now allowed pharmacy owners to close their pharmacies on Saturdays. The PDA is worried that a pharmacy closure could have negative impact on patients and other parts of the NHS, including neighbouring pharmacies, addiction and mental health services, and minor injury and A&E units. The association claims that there are record numbers of registered pharmacists who are available to work and therefore a decision to close a pharmacy over staff shortages is misleading. "The business owners may claim there is a shortage of pharmacists, but when they actively cancel agreed hours of work it does not suggest there is a shortfall of workers," said the PDA, adding: "These business decisions often include closing their pharmacies at very short notice, even when pharmacists are available and willing to work."

The Pharmacists' Defence Association (PDA) has raised concern over the Health Education England (HEE)'s decision on cutting funding to independent prescribing training. The HEE has reportedly decided that no funding will be available to back-fill trainees undertaking the pharmacist independent prescribing (PIP) qualification, or for the supervision of trainees by DPPs and DMPs. The PDA noted that, whilst all successful trainee pharmacists will be entering the GPhC register as independent prescribers from 2026, the existing pharmacist workforce is reliant on opportunities to undertake prescriber training through release from their employment, and the ability to secure a Designated Medical Practitioner (DMP) or Designated Prescribing Practitioner (DPP) to support the 90 days of supervised practice required. The association said it has already heard examples of potential DMPs or DPPs requesting a significant fee from trainees before they will provide supervision, adding that meeting that request is not an option for many. "This latest decision threatens to undermine the availability of the large numbers of pharmacists seeing supervisors as more IP training becomes available," it said in a statement.

In response to concerns raised by Community Pharmacy England (CPE), ministers have decided to lower the October threshold for the Pharmacy First service to 20. This decision addresses a major worry for pharmacy owners who have struggled to meet the required number of clinical pathways for monthly Pharmacy First payments, especially as the October increase to 30 pathways approached. CPE has been actively engaged in discussions with the Department of Health and Social Care and NHS England over the past few weeks to address this issue. Commenting on the decision, Janet Morrison, CEO of Community Pharmacy England, said: "It is great that ministers have responded to our concerns about another increase to the Pharmacy First payment threshold: this decision will save many community pharmacies from missing out on a vital payment this month." Morrison added that CPE will continue to monitor service data and, if needed, make further representations to ministers about future months. She also emphasised the need to find a long-term solution, which involves "NHS England marketing Pharmacy First effectively and ensuring that GPs are actively referring people to the service."

For years I wondered, "How is Christian planning and decision-making different? How do I safeguard we are "carrying out plans" that are God's and not our own

The Pharmaceutical Services Negotiating Committee (PSNC) has refused to accept the Department of Health and Social Care (DHSC)'s decision to get rid of 'transitional payments' from February 2023. The pharmacy negotiator said that 'any reductions in payments at this point will be impossible for community pharmacy contractors to manage financially.' "We are also continuing to be clear with officials and ministers that CPCF funding needs an urgent uplift to help businesses to cope with soaring costs being driven by inflation and the workforce crisis. We put a comprehensive business case to the government for this uplift in the last CPCF negotiations." The latest 'transitional payments decision' by the Department follows the announcement last year that the value of the these payments would be phased down over the second half of 2022/23 and will be based on the latest monitoring and analysis of funding delivery. PSNC says it submitted a fully-costed bid for a 'Pharmacy First' service in its last round of negotiations alongside the case for an uplift to core CPCF funding. Both of these were refused.

Addressing the recent announcement made by the Department of Health and Social Care (DHSC) to claw back £9 million per month from community pharmacy contractors, the Chairman of Numark, Harry McQuillan has expressed deep concerns over the financial implications on the sector. The claw back follows an error in the July calculations of Category M medicine prices, which led to increase in the reimbursements made to community pharmacies. Beginning August, the DHSC is set to claw back the amount. McQuillan criticised the decision, highlighting the severe strain it places on already financially vulnerable community pharmacies. Calling it "a severe blow to an already financially strained sector", McQuillan emphasised that the additional burden has the potential to threaten the viability of many pharmacies. "Community pharmacies are the frontline of our healthcare system, by penalising these pharmacies for an error not of their making, the Department of Health is jeopardising the foundation of local healthcare delivery," McQuillan criticised. Addressing the recent announcement made by the Department of Health and Social Care (DHSC) to claw back £9 million per month from community pharmacy contractors, the Chairman of Numark, Harry McQuillan has expressed deep concerns over the financial implications on the sector. The claw back follows an error in the July calculations of Category M medicine prices, which led to increase in the reimbursements made to community pharmacies. Beginning August, the DHSC is set to claw back the amount. McQuillan criticised the decision, highlighting the severe strain it places on already financially vulnerable community pharmacies. Calling it "a severe blow to an already financially strained sector", McQuillan emphasised that the additional burden has the potential to threaten the viability of many pharmacies. "Community pharmacies are the frontline of our healthcare system, by penalising these pharmacies for an error not of thei

Coeliac UK has raised grave concerns about the decision by NHS Leicester, Leicestershire and Rutland Integrated Care Board (ICB) to withdraw gluten free prescriptions for people with a diagnosis of coeliac disease and its potential impact on their health. The charity highlighted the significant additional cost of gluten free staple substitute products, which poses a real challenge to maintaining the gluten free diet, the only treatment for the condition. Coeliac UK noted that 72 per cent of respondents to a recent public consultation disagreed with the ICB's proposal to stop gluten free prescribing, and said it is "deeply concerned" by the potential impact of the decision to proceed with removal of provision. The charity accused the ICB of making no meaningful effort to reduce the impact of this policy change for those on low incomes, despite the additional cost of gluten free food being highlighted by 58 per cent of those who disagreed with the proposal.

The body size differences are paralleled by maturational changes. The smaller body of an infant or neonate is substantially different physiologically from that of an adult. Congenital defects, genetic variance, and developmental issues are of greater concern to pediatricians than they often are to adult physicians.

A major difference between pediatrics and adult medicine is that children are minors and, in most jurisdictions, cannot make decisions for themselves. The issues of guardianship, privacy, legal responsibility and informed consent must always be considered in every pediatric procedure. In a sense, pediatricians often have to treat the parents and sometimes, the family, rather than just the child. Adolescents are in their own legal class, having rights to their own health care decisions in certain circumstances. In basic terms, pediatricians take care of all of the children's needs from emotional support to medical support.

Wheelchair india as Pediatric Wheelchair Manufacturers and Pediatric Wheelchair supplier sale at low cost - price, We Sale online Pediatric Powered Wheelchair and Pediatric Electric Wheelchair at wholesale prices...

Wheelchairs - What to Consider Before You Buy

Electric wheelchairs are the correct decision for somebody that comes up short on the abdominal area quality important to utilize a manual wheelchair. Here you can find out about the kinds of seats accessible and the interesting points previously you purchase.

Fixed footrest wheelchair



The manual seat is presumably the correct decision for somebody that will just need it for a brief time frame, despite the fact that offering an utilized electric wheelchair is less demanding than offering a manual. The distinction in cost is noteworthy. Power wheelchairs cost three to four times more than manuals.

Obviously, control seats fluctuate incredibly in cost and not just on account of configuration focal points or highlights. The maker's recommended retail cost is now and then four fold the amount of as what a discounter charges.

When you choose the highlights you require, it is a smart thought to do some relative shopping. The web has made it conceivable to effortlessly look at results of numerous types.

Weight is an imperative thought. Your weight and the heaviness of the seat should both be considered.

Standing Wheelchairs Paraplegic

There may come a time in our lives when we find ourselves planning a funeral. It may be a loved one or even for us if we like getting a good head start on the inevitable. The entire process of planning a funeral can be very emotional, and we may feel overwhelmed throughout the process. However, deciding on a funeral home is a delicate decision. It is best to be well informed consider everyone's opinions. To help make the difficult decision more comfortable, we have gathered a few things for you to find when choosing the best funeral home for your needs.

The clinical decision support systems market is projected to reach USD 1,752.0 Million by 2023 from USD 901.0 Million in 2017, at a CAGR of 11.8%. Factors such as government support & initiatives, growing incidence of medication errors, rising prominence & usage of big data and mhealth tools, high returns on investment for CDSS solutions, and growing adoption of cloud computing in healthcare are driving the growth of this market.

The 21st edition of the Pharmacy Business Awards have been postponed due to a dramatic rise in the number of Omicron cases nationwide in recent months. The in-person event - initially scheduled to be held on February 3 - will now be held on Wednesday March 23 in central London. The awards dinner hosted by the Asian Media Group - owners of Pharmacy Business - was initially scheduled to be held on February 3. "Given the uncertainties around Omicron and the impact it could have on our community, we have taken the difficult decision to postpone the twenty-first edition of the Pharmacy Business Awards," an AMG spokesperson said, adding: "We feel this is the best and safest decision for our award winners, guests and partners."

Major Highlights of the Sugar Beet Seeds Market report study: A detailed look at the global Sugar Beet Seeds Industry The report analyzes the global Sugar Beet Seeds market and provides its stakeholders with significant actionable insights The report has considered all the major developments in the recent past, helping the users of the report with recent industry updates The report study is expected to help the key decision-makers in the industry to assist them in the decision-making process The study includes data on market intelligence, changing market dynamics, current and expected market trends, etc. The report comprises an in-depth analysis of macroeconomic and microeconomic factors affecting the global Sugar Beet Seeds market Market Ecosystem and adoption across market regions Major trends shaping the global Sugar Beet Seeds market Historical and forecast size of the Sugar Beet Seeds market in terms of Revenue (USD Million) Recent industry development and consumer preference trends Competitive Landscape and player positioning analysis for the global Sugar Beet Seeds market Key products and solution offerings by major players and business strategies adopted Recommendations for new market entrants and current players operating in the market space Analysis of niche and potential segments (type, application, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations Get FREE PDF Copy @ https://www.marketresearchstore.com/sample/sugar-beet-seeds-market-794502?utm_source=diigo.com-VPL&utm_medium=Varsha